GLP-1 Coverage for Weight Loss: What Self-Funded Employers Need to Think Through

I don't think the answer is as simple as yes or no. Obesity is a real health issue. It is tied to diabetes, heart disease, hypertension, sleep apnea, joint problems, and a long list of other conditions that eventually show up inside the health plan. Employers are already paying for many of the downstream consequences of poor metabolic health. They may just be paying for them later, in different parts of the plan. That is one side of the argument. The other side is cost. These medications are expensive, utilization can grow quickly, and the financial impact on a self-funded plan can be significant. An employer that opens the door without a clear strategy may find themselves funding a very large pharmacy expense without knowing whether the plan is actually improving health outcomes or simply adding cost.

That is where I think the conversation needs to be more disciplined. This should not be treated as a simple pharmacy decision. It should be treated as a plan management decision. There is a meaningful difference between covering GLP-1s as part of a broader clinical strategy and simply adding them to the formulary because employees are asking for them. One can be intentional. The other can become a blank check.

If an employer is considering coverage for weight loss, there need to be guardrails. Who qualifies? Are we following FDA-approved indications? Are there BMI and comorbidity requirements? Is there clinical oversight? Are members participating in nutrition, lifestyle, or coaching support? Are we measuring adherence? Are we tracking outcomes? Are we reviewing the data regularly to see whether the spend is producing value? Those questions matter because self-funded employers are not just buying insurance. They are funding the actual claims. That is also why I am not a fan of blanket answers on this topic. A blanket exclusion may be simple, but it could ignore a real opportunity to improve health and avoid larger claims down the road. Broad unmanaged coverage may feel generous, but it can create a cost problem that becomes hard to unwind later.

Cover GLP-1s for diabetes when clinically appropriate. Consider weight-loss coverage for members who meet specific clinical criteria. Use prior authorization that is clinically meaningful, not just administratively frustrating. Pair the medication with lifestyle support and ongoing follow-up. Understand the true net cost through the PBM. Monitor the results. Make adjustments based on data. That is the advantage self-funded employers have. They do not have to accept a one-size-fits-all answer. They can build a strategy around their population, claims experience, budget, risk tolerance, and long-term goals. But they have to be intentional.

GLP-1 coverage should not be decided in a vacuum. HR, finance, the consultant, the PBM, clinical partners, and leadership all need to understand what problem they are trying to solve. Is the goal employee satisfaction? Chronic condition management? Cardiovascular risk reduction? Diabetes prevention? Long-term claim mitigation? Those are not all the same strategy. The employers that handle this well will not be the ones that simply say yes or no. They will be the ones that define what success looks like before they start paying the claims. For some employers, GLP-1 coverage for weight loss may make sense. For others, it may not be the right financial decision yet. But every self-funded employer should be asking the same basic question: Are we just covering an expensive medication, or are we building a managed strategy around metabolic health? That distinction matters. Because in a self-funded plan, unmanaged good intentions can get expensive very quickly.